Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study

Lignende værker

• Patient‐reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: Neurotoxicity and adherence data from the ECOG ACRIN cancer research group E2511 phase II randomized trial
  af: Steffen McLouth, Laurie E., et al.
  Udgivet: (2020)
• A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E2511)
  af: Owonikoko, Taofeek K., et al.
  Udgivet: (2015)
• Impact of Genetic Ancestry on Outcomes in ECOG-ACRIN-5103
  af: Schneider, Bryan P., et al.
  Udgivet: (2017)
• E5501 - Phase II Study of Topotecan Sequenced with Etoposide/Cisplatin, and Irinotecan/Cisplatin Sequenced with Etoposide for Extensive Stage Small Cell Lung Cancer
  af: Owonikoko, Taofeek K., et al.
  Udgivet: (2013)
• Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second- or third-line treatment of patients with EGFR wild-type advanced non-small cell lung cancer (ECOG-ACRIN 1512): a phase 2 randomised controlled trial
  af: Neal, Joel W., et al.
  Udgivet: (2016)